146 related articles for article (PubMed ID: 35934601)
1. Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).
Ma TM; Chu FI; Sandler H; Feng FY; Efstathiou JA; Jones CU; Roach M; Rosenthal SA; Pisansky T; Michalski JM; Bolla M; de Reijke TM; Maingon P; Neven A; Denham J; Steigler A; Joseph D; Nabid A; Souhami L; Carrier N; Incrocci L; Heemsbergen W; Pos FJ; Sydes MR; Dearnaley DP; Tree AC; Syndikus I; Hall E; Cruickshank C; Malone S; Roy S; Sun Y; Zaorsky NG; Nickols NG; Reiter RE; Rettig MB; Steinberg ML; Reddy VK; Xiang M; Romero T; Spratt DE; Kishan AU;
Eur Urol; 2022 Nov; 82(5):487-498. PubMed ID: 35934601
[TBL] [Abstract][Full Text] [Related]
2. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.
Kishan AU; Chu FI; King CR; Seiferheld W; Spratt DE; Tran P; Wang X; Pugh SE; Sandler KA; Bolla M; Maingon P; De Reijke T; Nickols NG; Rettig M; Drakaki A; Liu ST; Reiter RE; Chang AJ; Feng FY; Sajed D; Nguyen PL; Kupelian PA; Steinberg ML; Boutros PC; Elashoff D; Collette L; Sandler HM
Eur Urol; 2020 Feb; 77(2):201-208. PubMed ID: 31718822
[TBL] [Abstract][Full Text] [Related]
3. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.
Sandler KA; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Song DY; Klein EA; Stephenson AJ; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco SC; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR; Kishan AU
Eur Urol; 2020 Jan; 77(1):3-10. PubMed ID: 30992160
[TBL] [Abstract][Full Text] [Related]
4. Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.
Hayman J; Phillips R; Chen D; Perin J; Narang AK; Trieu J; Radwan N; Greco S; Deville C; McNutt T; Song DY; DeWeese TL; Tran PT
Prostate; 2018 Jun; 78(8):623-630. PubMed ID: 29520847
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract][Full Text] [Related]
6. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology.
Kang JJ; Reiter RE; Steinberg ML; King CR
Eur Urol Oncol; 2018 Oct; 1(5):378-385. PubMed ID: 31158076
[TBL] [Abstract][Full Text] [Related]
7. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation.
Fuks Z; Leibel SA; Wallner KE; Begg CB; Fair WR; Anderson LL; Hilaris BS; Whitmore WF
Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):537-47. PubMed ID: 1869452
[TBL] [Abstract][Full Text] [Related]
8. Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study.
Tumati V; Jackson WC; Abugharib AE; Raj G; Roehrborn C; Lotan Y; Courtney K; Bagrodia A; Gahan JC; Zumsteg ZS; Folkert MR; Laine AM; Hannan R; Spratt DE; Desai NB
BJU Int; 2018 Mar; 121(3):365-372. PubMed ID: 28581200
[TBL] [Abstract][Full Text] [Related]
9. Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up.
Lazarev S; Thompson MR; Stone NN; Stock RG
BJU Int; 2018 May; 121(5):781-790. PubMed ID: 29319928
[TBL] [Abstract][Full Text] [Related]
10. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
11. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
Xie W; Regan MM; Buyse M; Halabi S; Kantoff PW; Sartor O; Soule H; Berry D; Clarke N; Collette L; D'Amico A; Lourenco RA; Dignam J; Eisenberger M; James N; Fizazi K; Gillessen S; Loriot Y; Mottet N; Parulekar W; Sandler H; Spratt DE; Sydes MR; Tombal B; Williams S; Sweeney CJ;
J Clin Oncol; 2020 Sep; 38(26):3032-3041. PubMed ID: 32552276
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.
Zelefsky MJ; Pei X; Chou JF; Schechter M; Kollmeier M; Cox B; Yamada Y; Fidaleo A; Sperling D; Happersett L; Zhang Z
Eur Urol; 2011 Dec; 60(6):1133-9. PubMed ID: 21889832
[TBL] [Abstract][Full Text] [Related]
13. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
[TBL] [Abstract][Full Text] [Related]
14. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.
Zhao SG; Lehrer J; Chang SL; Das R; Erho N; Liu Y; Sjöström M; Den RB; Freedland SJ; Klein EA; Karnes RJ; Schaeffer EM; Xu M; Speers C; Nguyen PL; Ross AE; Chan JM; Cooperberg MR; Carroll PR; Davicioni E; Fong L; Spratt DE; Feng FY
J Natl Cancer Inst; 2019 Mar; 111(3):301-310. PubMed ID: 30321406
[TBL] [Abstract][Full Text] [Related]
15. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
16. Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival.
Jackson WC; Suresh K; Tumati V; Allen SG; Dess RT; Salami SS; George A; Kaffenberger SD; Miller DC; Hearn JWD; Jolly S; Mehra R; Hollenbeck BK; Palapattu GS; Schipper M; Feng FY; Morgan TM; Desai NB; Spratt DE
Eur Urol; 2018 Oct; 74(4):413-419. PubMed ID: 29306514
[TBL] [Abstract][Full Text] [Related]
17. Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy.
Ying J; Wang CJ; Yan J; Liauw SL; Straka C; Pistenmaa D; Xie XJ; Lotan Y; Roehrborn C; Kim DN
Am J Clin Oncol; 2017 Dec; 40(6):612-620. PubMed ID: 26165416
[TBL] [Abstract][Full Text] [Related]
18. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
19. Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.
Kishan AU; Wang X; Seiferheld W; Collette L; Sandler KA; Sandler HM; Bolla M; Maingon P; De Reijke T; Hanks GE; Nickols NG; Rettig M; Drakaki A; Reiter RE; Spratt DE; Kupelian PA; Steinberg ML; King CR
JAMA Oncol; 2019 Jan; 5(1):91-96. PubMed ID: 30326032
[TBL] [Abstract][Full Text] [Related]
20. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
